Clinical Learning Study for a Mobile Smoking Cessation Program
- Conditions
- Smoking ReductionSmoking CessationSmoking BehaviorsSmoking, CigaretteNicotine DependenceSmoking
- Interventions
- Device: Clickotine®
- Registration Number
- NCT04857515
- Lead Sponsor
- Click Therapeutics, Inc.
- Brief Summary
The purpose of this study are to obtain learnings regarding the Digital Therapeutic (DTx) experience of Clickotine, including acceptability and preference of the overall program and specific DTx components, as well as to obtain learnings related to adult participants' use of the DTx for smoking cessation.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 78
-
Signed informed consent.
-
Age 18 and older.
-
For cigarette smokers: Smokes at least 5 cigarettes a day. For dual-users: Smokes cigarettes AND uses e-cigarettes, with the following additional criteria:
- Smokes at least 5 cigarettes a day
- Vaping sessions, when they occur, must be for at least 10 minutes (15 puffs)
-
Fluent in written and spoken English (confirmed by ability to read and comprehend the informed consent form)
-
Lives in the United States.
-
Is the solo user of an iPhone with iPhone operating system (iOS)13 or greater capabilities or a smart phone with an Android operating system (OS) 9 or greater capabilities.
-
Has an active email address.
-
Willing and able to receive SMS text messages on their smartphone and email messages.
-
Have access to internet connection during the study duration.
-
Able to confirm download of installed DTx on baseline date.
-
Willing and able to comply with study protocol and assessments.
-
Is willing and able to self-identify sessions of cigarette smoking (1 or more consecutive cigarettes) or vaping (approximately 15 puffs or around 10 minutes in duration) and log those sessions.
-
Self-reported comfort with and ability to use smartphone apps/programs.
- Prior use of Clickotine.
- Currently using a software app for smoking cessation.
- Lifetime diagnosis of schizophrenia, psychotic disorder, or pervasive developmental disorders, as per participant self-report.
- Any unstable medical illnesses including hepatic, renal, gastroenterological, respiratory, cardiovascular, endocrine, neurologic (including history of severe head injury with loss of consciousness), immunologic, or hematologic disease, as per participant self-report.
- Other significant medical condition that, in the opinion of the Investigator or study sponsor, may cofound the interpretation of device efficacy, safety, and tolerability.
- Current use of tobacco-containing products other than cigarettes or e-cigarettes (e.g. snuff, chewing tobacco, cigars, or pipes).
- Does not have or is unwilling to create a PayPal account
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Cigarette Smokers Clickotine® Adult cigarette smokers who only smoke combustible cigarettes Dual-Users Clickotine® Adult smokers who smoke both combustible cigarettes and vape
- Primary Outcome Measures
Name Time Method The main outcome of the Clickotine Learning Study is to determine engagement with the digital intervention (DTx). 4 Months Engagement with the digital intervention will be measured via app use for all participants
The main outcome of the Clickotine Learning Study is to determine acceptability of the digital intervention (DTx). 4 Months General acceptability of the DTx will be evaluated via surveys for all participants
The main outcome of the Clickotine Learning Study is to evaluate attitudes and beliefs regarding the digital intervention. 4 Months Attitudes and beliefs regarding the digital intervention will be evaluated by interview for selected participants
- Secondary Outcome Measures
Name Time Method The secondary outcome of the Clickotine Learning Study is to measure engagement levels with the digital intervention for cigarette smokers as compared to dual-users 4 Months These engagement levels will be measured via app use.
The secondary outcome of the Clickotine Learning Study is to determine acceptability of the digital intervention for cigarette users as compared to dual-users 4 Months Acceptability of the digital intervention will be evaluated via survey
Trial Locations
- Locations (1)
Click Therapeutics
🇺🇸New York, New York, United States